Cilengitide

DB11890InvestigationalSmall molecule

Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.

Mechanism: Pharmacologically active on Integrin beta-3, Integrin alpha-V, and Integrin beta-5
Curator reviewed
Formula / weight: C₂₇H₄₀N₈O₇ · 588.666 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyAMLYAMJWYAIXIA-VWNVYAMZSA-NSMILESCC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O

Targets

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

29Clinical trialsPhase, status and sponsor resolved per trial

20+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cilengitide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.